Drug Profile

AMG 732

Alternative Names: AMG-732; HZN 280

Latest Information Update: 04 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amgen
Class Eye disorder therapies
Mechanism of Action Insulin-like growth factor I inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Graves ophthalmopathy

Most Recent Events

25 Feb 2026 Amgen plans a phase II HAZEL 401 trial for Graves ophthalmopathy in February 2026 (SC) (NCT07438405)
26 Aug 2025 Phase-II clinical trials in Graves ophthalmopathy in USA (SC) (Amgen pipeline, August 2025)
30 May 2024 Phase-I/II clinical trials in Graves ophthalmopathy in USA (SC) (NCT06401044)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com